Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Mitsudomi

Showing results (21-30 of 336) with videos related to

Pageof 34
Sort By:
Cancer Science|June 21, 2016
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyYoshihisa Kobayashi, Tetsuya Mitsudomi
Current Opinion in Oncology|November 13, 2020
Adjuvant therapy of operable nonsmall cell lung cancer: an updateTetsuya Mitsudomi, Junichi Soh
Surgery Today|February 25, 2010
Small peripheral lung adenocarcinoma: clinicopathological features and surgical treatmentTakayuki Fukui, Tetsuya Mitsudomi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2017
[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation]Hidetoshi Hayashi, Tetsuya Mitsudomi
Molecular Cancer Research : MCR|August 1, 2013
Unintentional weakness of cancers: the MEK-ERK pathway as a double-edged swordKenichi Suda, Tetsuya Mitsudomi
Progress in Tumor Research|April 15, 2014
Successes and limitations of targeted cancer therapy in lung cancerKenichi Suda, Tetsuya Mitsudomi
Cells|February 12, 2021
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and LimitationsShuta Ohara, Kenichi Suda, Tetsuya Mitsudomi
Frontiers in Oncology|June 2, 2012
A Screening Method for the ALK Fusion Gene in NSCLCYoshiko Murakami, Tetsuya Mitsudomi, Yasushi Yatabe
International Journal of Clinical Oncology|July 20, 2006
Biological and clinical implications of EGFR mutations in lung cancerTetsuya Mitsudomi, Takayuki Kosaka, Yasushi Yatabe
Expert Opinion on Emerging Drugs|July 4, 2020
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancerToshio Fujino, Kenichi Suda, Tetsuya Mitsudomi
Pageof 34

Showing results (21-30 of 336) with videos related to

Sort By:
Pageof 34
Cancer Science|June 21, 2016
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyYoshihisa Kobayashi, Tetsuya Mitsudomi
Current Opinion in Oncology|November 13, 2020
Adjuvant therapy of operable nonsmall cell lung cancer: an updateTetsuya Mitsudomi, Junichi Soh
Surgery Today|February 25, 2010
Small peripheral lung adenocarcinoma: clinicopathological features and surgical treatmentTakayuki Fukui, Tetsuya Mitsudomi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2017
[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation]Hidetoshi Hayashi, Tetsuya Mitsudomi
Molecular Cancer Research : MCR|August 1, 2013
Unintentional weakness of cancers: the MEK-ERK pathway as a double-edged swordKenichi Suda, Tetsuya Mitsudomi
Progress in Tumor Research|April 15, 2014
Successes and limitations of targeted cancer therapy in lung cancerKenichi Suda, Tetsuya Mitsudomi
Cells|February 12, 2021
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and LimitationsShuta Ohara, Kenichi Suda, Tetsuya Mitsudomi
Frontiers in Oncology|June 2, 2012
A Screening Method for the ALK Fusion Gene in NSCLCYoshiko Murakami, Tetsuya Mitsudomi, Yasushi Yatabe
International Journal of Clinical Oncology|July 20, 2006
Biological and clinical implications of EGFR mutations in lung cancerTetsuya Mitsudomi, Takayuki Kosaka, Yasushi Yatabe
Expert Opinion on Emerging Drugs|July 4, 2020
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancerToshio Fujino, Kenichi Suda, Tetsuya Mitsudomi
Pageof 34